Services

Cell Line Development

7-14 g/L clone titers
5-week stable pools
>95% stability at 60 gen
2.5 mo to IND-ready

Value drivers

Start with pools.
Clone when ready

Traditional cell line development is a 4-7 month gauntlet of optimization screens – vector, codon, signal peptide, pool, minipool, bioreactor – most of which exist only to compensate for poorly optimized vectors, signal peptides, codon optimization tools, and host cell lines.

Every one of those screens is a month you’re paying for, not a month in the clinic.

Alternative Systems

Codon optimization screening
Signal peptide screening
Vector optimization screens
Pool / minipool screening
Bioreactor screening
4-7 month timeline

Celltheon CLD

Eliminated – universal pGL™
Eliminated – platform peptide
Eliminated – one vector, every modality
Pool IS the screen
Platformed process – no screening
2.5-4 months to IND-ready

Scientists working together in the laboratory

How it works

Celltheon’s CLD platform integrates GOLDILOCKS™ transposase, SUPERCELL™ CHO-K1, GL™ universal vectors, and ELIXIR™ media + feeds as a co-optimized system. No per-molecule customization.

WEEK 1-2
Gene → Vector
- Codon-optimize + synthesize
- Clone into pGL™ universal vector
- Sanger-confirm; endo-free plasmid prep
WEEK 2-5
Transfection → Stable Pool
- GOLDILOCKS™ + plasmid co-delivered
- 15-20 single-copy integration sites
- Pool titer & CQA in hand at Week 5
WEEK 5-10
Subcloning → Top Clones
- VIPS® PRO + Solentim imaging (ICH Q5D)
- 300-clone Octet ProA BLI screen
- Top 15 CQA → top 5 for RCB
WEEK 10-18
RCB → Stability → IND-Ready
- RCB – Stability -> IND-
- Ready
OUTPUT
Sequence → IND-ready RCB in 14 weeks
- No optimization screens, no rework

Decision gates

A staged CLD engagement model that lets teams prove the molecule first, then scale into a full clone campaign

Start with a focused, lower-commitment stage to evaluate performance early.Each step creates a clear decision point before moving into deeper development, helping teams reduce risk, control spend, and accelerate the path from gene to RCB.

Pool evaluation
Prove out the molecule in 5 weeks

Gene synthesis → stable pool + fed-batch CQA. Accessible entry-point pricing, designed for go/no-go decisions.

Ideal for: Program de-risking, early biology readouts, parallel candidate screening

Talk to a Scientist
Differentiated

Park at pool
The hidden timeline accelerator

Complete the Pool Eval, then pause. Pool sits in LN2 storage. On resume, CLD compresses from 2.5 to 1.5 months.

Ideal for: Programs gated on funding, IP, biology readouts, or partner timelines

Talk to a Scientist
À la catre
Sequence to characterized CB in 10 weeks

Pool – 300-clone screen – Top-5 RCB -> 60-gen stability with NGS. ICH Q5D-aligned reports.

Ideal for: Funded programs heading to IND, biosimilars, scale-up partners

Talk to a Scientist
Bundled with CLD/PD
One contract, one team, gene to 50L

CLD + analytics + USP/DSP + formulation + 50L non GMP + tech transfer. ~6 months vs. 12+.

Ideal for: Lean biotechs, accelerated programs, IND-enabling tox tracks

Talk to a Scientist

Six Categories, Twenty-Two Assays

Built on the GOLDILOCKS™ platform

Every CLD program runs on Celltheon’s proprietary integrated stack.
Co-optimized components mean no per-molecule customization – the same workflow works for every modality.

Explore the GOLDILOCKS™ Stable CHO-K1 Kit for licensing & in-house use

Explore

GOLDILOCKS™ transposase

Multi-site single-copy integration into transcriptionally active chromatin. No concatemers, no rearrangements, no silencing over time.
SUPERCELL™ CHO-K1

Host engineered for high viability, scale-up consistency, and complex molecule support – bispecifics, ADCs, multi-chain fusions.
pGL™ universal vector

One construct, every modality – mAbs, bispecifics, ADCs, Fc-fusions, nanobody fusions. Cargo capacity to 100-200 kb.
ELIXIR™ media + feeds

AOF chemically defined media and feeds, co-optimized for SUPERCELL™ in batch, fed-batch, and perfusion modes.

Modalities supported

One universal vector, one workflow. Every modality runs on the same platform – no codon screens, no signal peptide screens, no per-molecule optimization.

mAbs (IgG, IgA, IgM)

7-10 g/L pool, 10-14 g/L clone.
Bispecific & multispecific

4+ chain support; HC:LC ratios preserved across integration sites.
Fc-fusion proteins

Pool titers documented >14 g/L;
top clones >17g/L.
Nanobody & single-domain

Custom productivity and purification assay development in house for nonstandard formats
ADCs (antibody side)

Codevelopment of mAb, conjugation, and payload
with TRIDENT™ for conjugation.
Enzymes, cytokines & beyond

Screen clones via kcat/Km and other nonstandard
product quality and characterization assays